Exodus Point Capital Management, LP Cardiff Oncology, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$1.17 - $2.61 $21,251 - $47,408	-18,164 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.11 - $7.25 $12,660 - $43,500	6,000 Added 49.33%	18,164 $45,000
Q4 2021 Feb 11, 2022	SELL	$5.18 - $7.24 $68,878 - $96,270	-13,297 Reduced 52.22%	12,164 $73,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $56,628 - $85,676	-11,303 Reduced 30.74%	25,461 $170,000
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $315,795 - $476,779	-47,488 Reduced 56.36%	36,764 $244,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $401,664 - $863,800	44,139 Added 110.04%	84,252 $780,000
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $482,158 - $991,192	40,113 New	40,113 $722,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.